
Merck has paid out $688 million to end two class-action lawsuits which sprang up after the revelation of disappointing trial …
NICE has approved Merck Sharp & Dohme and Schering-Plough's Ezetrol, but recommended the cheapest version be used – effectively blocking …
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board

